XML 26 R11.htm IDEA: XBRL DOCUMENT v3.19.2
GOODWILL AND OTHER INTANGIBLE ASSETS
 6 Months Ended
Jun. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]  
GOODWILL AND OTHER INTANGIBLE ASSETS GOODWILL AND OTHER INTANGIBLE ASSETS
Changes in the carrying amount of goodwill for the six-month period ended June 30, 2019 were as follows:
 
Codman Specialty
Surgical
 
Orthopedics and
Tissue Technologies
 
Total
 
(In thousands)
Goodwill at December 31, 2018
$
625,760

 
$
300,715

 
$
926,475

Foreign currency translation
174

 
83

 
257

Goodwill at June 30, 2019
$
625,934

 
$
300,798

 
$
926,732


The components of the Company’s identifiable intangible assets were as follows:
 
June 30, 2019
 
Weighted
Average
Life
 
Cost
 
Accumulated
Amortization
 
Net
 
(Dollars in thousands)
Completed technology
19 years
 
$
856,730

 
$
(190,219
)
 
$
666,511

Customer relationships
13 years
 
222,784

 
(111,617
)
 
111,167

Trademarks/brand names
28 years
 
104,041

 
(26,688
)
 
77,353

Codman trade name
Indefinite
 
162,466

 
—

 
162,466

Supplier relationships
27 years
 
34,721

 
(17,233
)
 
17,488

All other
4 years
 
10,913

 
(4,278
)
 
6,635

 
 
 
$
1,391,655

 
$
(350,035
)
 
$
1,041,620


 
December 31, 2018
 
Weighted
Average
Life
 
Cost
 
Accumulated
Amortization
 
Net
 
(Dollars in thousands)
Completed technology
19 years
 
$
855,679

 
$
(167,384
)
 
$
688,295

Customer relationships
13 years
 
231,448

 
(106,859
)
 
124,589

Trademarks/brand names
28 years
 
104,061

 
(24,764
)
 
79,297

Codman trade name
Indefinite
 
162,054

 
—

 
162,054

Supplier relationships
27 years
 
34,721

 
(16,519
)
 
18,202

All other 
4 years
 
10,958

 
(3,899
)
 
7,059

 
 
 
$
1,398,921

 
$
(319,425
)
 
$
1,079,496


Based on quarter-end exchange rates, amortization expense (including amounts reported in cost of product revenues) is expected to be approximately $32.6 million for the remainder of 2019, $65.2 million in 2020, $64.1 million in 2021, $60.6 million in 2022, $59.8 million in 2023, $58.9 million in 2024 and $535.6 million thereafter.
In April 2019, a contract manufacturing customer of our Private Label product line received a notification from the FDA ordering them to remove their product from the market. During the second quarter of 2019, the Company recorded an impairment charge of $5.8 million in intangible asset amortization in the consolidated statement of operations related to the customer relationship intangible asset acquired from TEI Biosciences, Inc. and TEI Medical Inc. (collectively "TEI") due to revised future projections based on a pending contract termination.